and patients have questions on where these new medications fit in the pharmacologic strategy, and how originator TNFi, sulfasalazine, and NSAIDs should be used given these new options. Based on the current evidence and the considerations of the panel, NSAIDs and TNFi remain the primary classes of medications for the treatment of AS and nonradiographic axial SpA. Secukinumab or ixekizumab is recommended for patients with active disease who have heart failure or demyelinating disease as a